方法：选择2012-03/2014-03在我院眼科确诊为黄斑水肿的患者92例92眼为研究对象，按照玻璃体腔注射用药不同，分为曲安奈德组44例44眼和贝伐单抗组48例48眼，术后随访9mo，比较两组患者在不同时间点的最佳矫正视力、黄斑中央视网膜平均厚度和眼内压情况。

结果：术后随访9mo，两组患者术后的最佳矫正视力均比术前提高，但组间无统计学意义(P>0.05)； 经重复测量方差分析，两组患者的黄斑中央视网膜厚度无统计学意义(P>0.05)。曲安奈德组术后各时间点与术前的黄斑中央视网膜厚度差异具有统计学意义(t=9.16，8.27，5.44，5.87，4.62，P<0.05)，贝伐单抗组术后各时间点的斑中央视网膜厚度均比术前降低，具有统计学意义(t=8.11，5.12，4.16，3.27，2.88，P<0.05)； 曲安奈德组有7例患者发生眼压升高，并发为青光眼，贝伐单抗组患者未见眼压异常。

结论：曲安奈德和贝伐单抗均可提高黄斑水肿患者的矫正视力，改善毛细血管的渗漏情况，但贝伐单抗不会引起眼压升高，能避免其他并发症的发生，安全性更高。

METHODS:Ninety-two patients(92 eyes)diagnosed as macular edema were chosen for the study in the department of ophthalmology from March 2012 to March 2014 in our hospital. They were divided into two groups according to different intravitreal injection drugs, the triamcinolone acetonide group with 44 cases(44 eyes)and the bevacizumab group with 48 cases(48 eyes). They were followed up for 9mo after surgeries, and the best-corrected visual acuity(BCVA), the mean central retinal thickness, macular capillary angiographic results and intraocular pressure(IOP)were compared between the two groups at the same time points.

RESULTS:The BCVA of the two groups were both improved postoperatively, but there was no significant differences between the groups in the followed up for 9mo(P>0.05). By repeated measures analysis of variance, there was no significant difference on the central retinal macular thickness between the two groups(P>0.05). The differences on the central retinal macular thickness between the preoperative and each time point postoperative in the triamcinolone acetonide group were statistically significant(t=9.16,8.27,5.44,5.87,4.62, P<0.05), and the central retinal thickness at each time point postoperative was lower than that preoperative in the bevacizumab group, and the differences were statistically significant(t=8.11,5.12,4.16,3.27,2.88, P<0.05).Seven patients had increased IOP in the triamcinolone acetonide group, and became glaucoma, but there was no ocular abnormalities in the bevacizumab group.

CONCLUSION:Triamcinolone acetonide and bevacizumab can improve visual acuity and capillary leakage in patients with macular edema, but bevacizumab which can not cause increased IOP, can prevent other complications, with more security.